Reducing opioid misuse among adolescents through physician education.

Increased prescribing of opioids has been associated with an epidemic of nonmedical prescription opioid use in the United States; adolescents and young adults are particularly vulnerable to opioid misuse. The role of physicians as health care providers, educators, and confidants for their adolescent patients equips them to intervene in adolescent opioid misuse. The authors advocate for improving the education of physicians and residents regarding opioid use and misuse among adolescents. To achieve this, we can require residency education that includes opioid misuse and appropriate prescribing, widely disseminate existing resources on management of pain and opioid misuse, and develop pain management and addiction mentorship programs.

Implementing the Collaborative Care Model as Part of a Countywide Initiative.

This column describes the planning and implementation of an integrated behavioral health project which was facilitated and endorsed by a developing accountable health community, the Washtenaw Health Initiative (WHI). The WHI is a voluntary countywide coalition of academic, community, health system, and county government agencies dedicated to improving access to high-quality health care for low-income, uninsured, and Medicaid populations. When lack of access to mental health services was identified as a pressing concern, the WHI endorsed pilot testing of collaborative care, an evidence-based treatment model, in county safety-net clinics. Challenges, outcomes, and relevance of this initiative to other counties or regional entities are discussed.

Designer drugs 2015: assessment and management.

Recent designer drugs, also known as "legal highs," include substituted cathinones (e.g., mephedrone, methylone, and methylenedioxypyrovalerone, often referred to as "bath salts"); synthetic cannabinoids (SCs; e.g., Spice); and synthetic hallucinogens (25I-NBOMe, or N-bomb). Compound availability has evolved rapidly to evade legal regulation and detection by routine drug testing. Young adults are the primary users, but trends are changing rapidly; use has become popular among members of the military. Acute toxicity is common and often manifests with a constellation of psychiatric and medical effects, which may be severe (e.g., anxiety, agitation, psychosis, and tachycardia), and multiple deaths have been reported with each of these types of designer drugs. Clinicians should keep designer drugs in mind when evaluating substance use in young adults or in anyone presenting with acute neuropsychiatric complaints. Treatment of acute intoxication involves supportive care targeting manifesting signs and symptoms. Long-term treatment of designer drug use disorder can be challenging and is complicated by a lack of evidence to guide treatment.

Isolated shoulder weakness as a result of a cortical infarction in the precentral gyrus.

Since its discovery, our understanding of the primary motor cortex has continued to evolve. The presentations of rare, isolated, motor palsies of small muscle groups have heavily contributed to the characterization of the somatotopic representation of the human body on the cortex. We present a case of localized, left shoulder small muscle group weakness secondary to ischemic cerebral infarction in the primary motor cortex. The patient experienced full recovery over several days. Strokes causing isolated shoulder weakness are rare due to the relatively small area dedicated to shoulder motor function in the precentral gyrus. However, our patient presented with a larger area of infarction than in previously reported cases, demonstrating the large individual variability that may exist within the motor cortex somatotopic map.

A multifactorial intervention for hospital opioid management.

OBJECTIVE: To determine whether an educational intervention combined with a voluntary decision support system improves inpatient pain control. DESIGN: Retrospective serial cross-sectional study. SETTING: Community teaching hospital. PATIENTS: Patients admitted to internal medicine teaching service from October to December 2011 and 2012. The study cohorts consisted of a random sample of 75 patients each from both time periods. INTERVENTIONS: Beginning in August 2012, internal medicine residents participated in an interactive training session on the use of opioids for hospitalized patients and concurrently, a user initiated voluntary computerized decision support system (CDSS), in the form of computer order entry (COE) and pocket cards were introduced. The COE options correspond to the standardized opioid dosing regimen on the pocket card. Pain scores and opioid doses and demographic information were obtained from administrative databases. Additional covariates were abstracted via programmed electronic medical record (EMR) review. MAIN OUTCOME MEASURES: Pre- and postintervention, maximum reported pain score in every 8-hour period from first analgesic dose, to 72 hours after the first analgesic dose, were compared by fitting a multivariable linear mixed model. Naloxone use was a surrogate measure for secondary outcome of opioid overdose. RESULTS: The intervention had no effect on maximum pain score (MPS) over time, p = 0.0930. The estimated mean MPS (95% confidence interval) was 4.7 (3.9, 5.5) preintervention and 5.2 (4.4, 6.0) postintervention. CONCLUSIONS: A combination of a resident educational intervention, CDSS, and pocket cards did not improve MPSs over time for patients on an internal medicine teaching service.

A randomized trial of computer-delivered brief intervention and low-intensity contingency management for smoking during pregnancy.

INTRODUCTION: Implementation of evidence-based interventions for smoking during pregnancy is challenging. We developed 2 highly replicable interventions for smoking during pregnancy: (a) a computer-delivered 5As-based brief intervention (CD-5As) and (b) a computer-assisted, simplified, and low-intensity contingency management (CM-Lite). METHODS: A sample of 110 primarily Black pregnant women reporting smoking in the past week were recruited from prenatal care clinics and randomly assigned to CD-5As (n = 26), CM-Lite (n = 28), CD-5As plus CM-Lite (n = 30), or treatment as usual (n = 26). Self-report of smoking, urine cotinine, and breath CO were measured 10 weeks following randomization. RESULTS: Participants rated both interventions highly (e.g., 87.5% of CD-5As participants reported increases in likelihood of quitting), but most CM-Lite participants did not initiate reinforcement sessions and did not show increased abstinence. CD-5As led to increased abstinence as measured by cotinine (43.5% cotinine negative vs. 17.4%; odds ratio [OR] = 10.1, p = .02) but not for CO-confirmed 7-day point prevalence (30.4% abstinent vs. 8.7%; OR = 5.7, p = .06). Collapsing across CM-Lite status, participants receiving the CD-5As intervention were more likely to talk to a doctor or nurse about their smoking (60.5% vs. 30.8%; OR = 3.0, p = .02). CONCLUSIONS: Low-intensity participant-initiated CM did not affect smoking in this sample, but the CD-5As intervention was successful in increasing abstinence during pregnancy. Further research should seek to replicate these results in larger and more diverse samples. Should CD-5As continue to prove efficacious, it could greatly increase the proportion of pregnant smokers who receive an evidence-based brief intervention.

Bariatric surgery history among substance abuse treatment patients: prevalence and associated features.

BACKGROUND: In 2006, Brighton Hospital (Brighton, Michigan), a comprehensive substance abuse treatment facility, began observing increasing admissions who reported a history of bariatric surgery. Data on the magnitude of this postoperative outcome is lacking. The hospital instituted procedures to better track this variable in the electronic medical records at admission to estimate the prevalence of bariatric surgery history among substance abuse treatment admissions. METHODS: The data analyzed for the present report included the electronic medical record data obtained from 7199 patients admitted from 2006 to 2009 and the chart review data from 54 bariatric patients and 54 controls. RESULTS: The findings suggested that 2-6% of recent admissions were positive for a bariatric surgery history. The substance abuse treatment patients with a bariatric surgery history were significantly more likely to be women and nonsmokers. The bariatric and nonbariatric patients were equally likely to have been diagnosed with alcohol dependence; however, bariatric patients were significantly more likely to also have a diagnosis of alcohol withdrawal. Relative to the matched control cases, the alcohol-dependent bariatric patients reported consuming a significantly greater maximum quantity of drinks per drinking day. CONCLUSION: A bariatric surgery history might be overrepresented in substance use programs and such patients' recovery efforts might pose unique challenges.

Prescription drug use and abuse. Risk factors, red flags, and prevention strategies.

When a patient is in physical or emotional pain, prescribing controlled substances often appears to be the simplest and most efficient way to relieve suffering and distress. However, in a minority of cases, this approach leads to prescription drug abuse and patient harm. In this article, the authors review the epidemiologic factors of prescription drug abuse, legal policies designed to safeguard against it, risk factors and red flags, and practical ways to minimize the chances of misuse.

Injection drug use and wound care.

Persons who have injected drugs present challenges to providing wound care. They tend to have multiple physical and psychosocial problems and abuse many substances. They may mistrust health care providers because of past experiences and their perceived negative attitude toward providers. Because they often self-treat abscesses and wounds before seeking care, the infection or wound can be large. A complete history and physical examination should be obtained. All aspects of the person's background will have an impact on wound healing. Wounds need careful assessment and diagnosis. Correct diagnosis of the wound is critical for the proper treatment. Treatment decisions must also include pain control, financial concerns, living arrangements, insurance, and the person's ability to perform the care. Patient education is a critical link in enhancing positive wound healing outcomes.

A randomized trial of one-day vs. three-day buprenorphine inpatient detoxification protocols for heroin dependence.

Detoxification from opioids remains an important first step in the treatment of many patients with opioid dependence. Several pharmacologic regimens have been used for opioid detoxification. In the United States, the partial mu-opioid agonist, buprenorphine (BUP) is the most recently approved pharmacotherapy for opioid detoxification and replacement. The literature in recent years has described detoxification protocols using a single high dose of BUP and a three-day BUP regimen. In many settings, such as drug-free programs, a single-dose detoxification protocol would be of significant benefit. There have been no prior studies comparing one-day and three-day BUP-assisted opioid withdrawal. In this pilot study, we conducted an open-label, randomized trial of one-day vs. three-day BUP/naloxone sublingual tablet-assisted opioid withdrawal. Twenty patients from a therapeutic community treatment program were randomly assigned to receive either 32 mg sublingual BUP over one hour (one-day group), or 32 mg sublingual BUP over three days (three-day group). Nine of 10 subjects (90 percent) in each group completed seven days in the detoxification protocol. There was no statistically significant difference between the two groups in all other outcome variables, including retention in the treatment program, intensity of withdrawal signs and symptoms, amounts of adjunct medications used, and ability to produce opiate-free urine. This study further validates the feasibility of the single high dose of BUP as a rapid detoxification method.

Tobacco cessation: new challenges, new opportunities.

Throughout the 1990's tobacco use has continued to expand in the developing world, and patterns of use have begun to shift in developed countries. During this same period, our knowledge of effective tobacco cessation methods has dramatically increased. In this paper, we review global trends in tobacco use, and current strategies for tobacco cessation. Evolving work in genetics, pharmacology, counseling, cessation aides, training, systems approaches, and regulation all have the potential to deliver more effective interventions to more tobacco users. Reducing the worldwide tobacco burden will require complementary efforts to reduce initiation and promote cessation. Until effective tobacco cessation methods are widely disseminated and readily available, the tobacco death toll will continue to rise.

Injection drug use in North America.

Injection drug use of psychotropic agents for nontherapeutic purposes is associated with some of the most pernicious infectious diseases seen in the United States. There is an inextricable link between infection, injection drug use (IDU) and other risk behaviors, especially those related to sexual activity. A number of national surveys now provide excellent databases to track the breadth, scope and impact of IDU across the United States. The prevalence of heroin use has increased over the past decade with larger numbers of users presenting for treatment of drug use disorders. A host of serious infections can result from IDU. Prevention and early intervention with evidence-based harm-reduction strategies are crucial to reducing and eliminating these odious consequences.

Management of the hospitalized injection drug user.

Patients with a history of injected drug use are often distrustful of the medical system. This attitude is generally based on problems in the management of pain or withdrawal or on hostility from medical providers in the past. When treated with respect and appropriate medical concern, hospitalized injection drug users will often actively seek to begin recovery from drug use. Identifying injection drug use is the first step in providing appropriate care. Assessing and systematically addressing key management issues allows the provider to care for the hospitalized injection drug user effectively. The well-trained provider can be a significant catalyst for behavior change in the addicted population.

Effects of buprenorphine sublingual tablet maintenance on opioid drug-seeking behavior by humans.

RATIONALE: Buprenorphine can decrease opioid self-administration by humans and animals, but its ability to decrease drug-seeking behavior and craving (i.e. motivational measures) among outpatient volunteers using clinically relevant dosing schedules has not been extensively studied. OBJECTIVES: We investigated whether daily versus alternating-day administration of high versus low buprenorphine doses influenced choice of, and operant responding for, hydromorphone versus money. METHODS: Fourteen heroin-dependent outpatients were maintained under four buprenorphine sublingual tablet (double blind) dose conditions using a within-subject, randomized crossover design. All participants received, for 2 weeks each, buprenorphine doses of 2 mg daily, 4 mg/placebo on alternating days, 16 mg daily, and 32 mg/placebo on alternating days. In each laboratory test session, participants chose between money ($2/choice) and drug (1/8 of total hydromorphone, 4 or 24 mg IM in different sessions) alternatives using an eight-trial non-independent progressive ratio schedule (FR 100, 200,.12,800). The drug dose and money amount earned was delivered after the end of the 2.5-h work period. RESULTS: Hydromorphone 24 mg was more reinforcing than 4 mg. Higher versus lower average buprenorphine doses (regardless of daily versus alternate-day schedule) significantly decreased hydromorphone 24 mg choice and increased money choice. Baseline heroin craving questionnaire scores predicted drug choice, and craving scores were significantly decreased by high-dose buprenorphine. CONCLUSIONS: High-dose buprenorphine attenuated opioid drug-seeking behavior, heroin craving self-reports and increased sensitivity to alternative reinforcement. These beneficial effects were retained when high-dose buprenorphine was administered on alternate days.